PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Infectious Disease Library

The strides made over the last several years to accelerate infectious disease research and therapeutic development has been remarkable. Ensuring that you stay up to date with the latest ideas and discoveries, research enabling solutions, and thought leading trends is essential to your next breakthrough. We’ve made it simple with our infectious disease resource library, highlighting the work of your fellow colleagues.

Infectious Diseases

Virology Research

COVID-19 Therapeutics: Demand, Challenges, and the Future

In a recent panel discussion, Dr. Kevin Coombs, Dr. Randal Ketchem, Dr. Mansoor Amiji, and Dr. Seyoum Ayehunie provided insights into why developing effective COVID-19 treatments will play a significant role in controlling the pandemic. This whitepaper highlights the key discussion points addressed during the session.

The Impact of COVID-19 in Pharma: Current and Long-Term Expectations

Awareness continues to increase on the short and long-term impacts of COVID-19 on clinical research, drug development and manufacturing, and pharma industry regulation, which we will discuss in this article. As we move towards a new normal, it is important to take away some of the helpful solutions developed and implemented during this time of crisis.

Virus Vaccine Research and Development - Accelerated Workflows

The slow, linear, methodical process of the past is being reconstructed. In the sprint to protect the public's safety, clinical trial phases overlap instead of occurring sequentially. In the new paradigm, preclinical studies may occur in tandem with first-in-human studies. Phase 1 may intersect with Phase 2. And Phase 2 may crossover into Phase 3.

Lit Review: Current Approaches to Identify Possible COVID-19 Therapeutics

In the midst of the current COVID-19 pandemic, multiple approaches to identify potential therapeutics are being pursued. Most of the treatments in development fall into one of three categories: antivirals, antibodies, or protein-protein interaction inhibitors. This literature review provides an overview of each therapeutic approach and highlights some of the innovative work going on in the field.

NIH NCATS Case Study: Using Accelerated Screening Research for SARS-CoV-2 Drug Repurposing Candidates

Drug Repurposing can be an effective way to identify treatments for diseases, especially when time is of the essence. Research scientists at National Center for Advancing Translational Sciences (NCATS), a part of the NIH, embarked on a drug repurposing strategy as the quickest route to generating data that would help the pharma industry drive towards an effective treatment for the COVID-19 virus.

The Role of Preclinical Imaging in Viral and Bacterial Research

Watch this on demand webinar, presented by Dr. Kevin Francis, VP of Biology Solutions and Dr. Olivia Kelada, Senior Applications Scientist at PerkinElmer where they discuss how optical and microCT imaging provides versatile approaches to visualize and monitor host-pathogen interactions in animal models.

In Vivo Imaging of Influenza Virus Infection in Immunized Mice

Read how researchers at the NIH, NIAID, Emory University, and University of Wisconsin used the IVIS® optical imaging platform to successfully quantify and track viral load in mice and demonstrated that vaccine of human mAb administration has a protective or therapeutic effect in mice challenged with the influenza virus.

Remdesivir: Looking at the Technologies Behind the Discovery

The investigational antiviral drug remdesivir is produced by Gilead Sciences under the brand name Veklury® (remdesivir). Today, remdesivir is being prescribed under FDA emergency use authorization as a treatment for patients with COVID-19. It is also presently in numerous clinical trials worldwide. See the technologies behind the discovery.

Viral Research Brochure

The discovery of antivirals and vaccines has revolutionized medicine and saved billions of children from diseases such as polio and smallpox. But the high mutation rates and the existence of animal reservoirs contribute to the emergence of new pathogenic viruses with epidemic or pandemic potential. Simply put, we're far from fully understanding and being able to entirely control viral diseases and their outbreaks.


Targeting Leishmaniasis with an Entamoeba Molecule

Learn about the promising results Dr. Helena Fehling from the Department of Molecular Parasitology and Immunology at the Bernhard Nocht Institute for Tropical Medicine, is finding with an immune-therapeutic approach to leishmaniasis treatment.

Bacteria and Microbiome

Lit Review: Tackling Biofilm Formation

This article provides an overview of novel approaches to improve our understanding of biofilms and enhance the diagnosis and treatment of bacterial implant infections.

On-Demand Webinars

COVID -19 Therapeutics Panel Discussion

Watch this panel discussion to hear from top researchers about various approaches being pursued to develop effective treatments against SARS-CoV-2, the drug delivery systems being considered for the release of new therapeutics or vaccines, and how to ensure these medicines meet regulatory standards.